CD40LG and neoplasm: Considering our data, it is tempting to speculate that the joint effect of RANKL with CD40L leading to prolonged DC survival may prevent tumor growth; an additional argument for the potential benefit of CD40L linked with DC immunotherapy for breast cancer.